Serplulimab Plus Chemoradiotherapy vs Chemoradiotherapy as Adjuvant Treatment for Postoperative Cervical Cancer Patients With Multiple Risk Factors: A Randomized, Open-Label, Phase II Clinical Trial
Latest Information Update: 18 Dec 2024
Price :
$35 *
At a glance
- Drugs Serplulimab (Primary) ; Cisplatin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 18 Dec 2024 New trial record